4.8 Letter

Prevalence of Mismatch-Repair Deficiency in Rectal Adenocarcinomas

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Pathology

DNA Mismatch Repair-deficient Rectal Cancer Is Frequently Associated With Lynch Syndrome and With Poor Response to Neoadjuvant Therapy

Lama F. Farchoukh et al.

Summary: In this study, we found that MMR deficiency in rectal cancer is associated with a poor response to neoadjuvant therapy and a lower chance of pathologic downstaging. We also confirmed that MMR deficiency is strongly associated with a diagnosis of Lynch syndrome. These findings suggest that MMR status can help guide the selection of neoadjuvant treatment regimens and predict tumor response to neoadjuvant therapy.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2022)

Article Medicine, General & Internal

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer

Andrea Cercek et al.

Summary: This study found that mismatch repair-deficient, locally advanced rectal cancer is highly sensitive to PD-1 blockade. Additionally, no adverse events of grade 3 or higher have been reported, and no cases of progression or recurrence have been observed. Longer follow-up is needed to assess the duration of response.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Multidisciplinary Sciences

Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights

Olusegun Isaac Alatise et al.

Summary: Understanding the molecular and phenotypic profile of colorectal cancer (CRC) in West Africa is crucial for addressing the rising burden of disease, as shown by a study comparing Nigerian CRC patients to those from TCGA and MSKCC. High microsatellite instability, differences in genetic mutations, and presentation characteristics suggest a unique biology of CRC in Nigeria that requires tailored diagnostic and treatment approaches.

NATURE COMMUNICATIONS (2021)

Article Oncology

Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy

Andrea Cercek et al.

CLINICAL CANCER RESEARCH (2020)